Total Payments
$62,347
2024 Payments
$9,185
Companies
40
Transactions
662
Medicare Patients
15,963
Medicare Billing
$755,618
Payment Breakdown by Category
Research$17,303 (27.8%)
Travel$16,655 (26.7%)
Food & Beverage$11,880 (19.1%)
Other$11,859 (19.0%)
Consulting$4,398 (7.1%)
Education$252.61 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,303 | 36 | 27.8% |
| Travel and Lodging | $16,655 | 53 | 26.7% |
| Food and Beverage | $11,880 | 560 | 19.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,859 | 5 | 19.0% |
| Consulting Fee | $4,398 | 2 | 7.1% |
| Education | $252.61 | 6 | 0.4% |
Payments by Type
General
$45,044
626 transactions
Research
$17,303
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $18,141 | 33 | $0 (2024) |
| Novo Nordisk Inc | $10,739 | 50 | $0 (2024) |
| Novo Nordisk AS | $6,528 | 18 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $6,269 | 38 | $0 (2022) |
| PFIZER INC. | $3,784 | 77 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $3,057 | 26 | $0 (2022) |
| ABBVIE INC. | $2,346 | 43 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,472 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,378 | 66 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,376 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,185 | 108 | Eli Lilly and Company ($3,549) |
| 2023 | $3,659 | 77 | Boehringer Ingelheim International GmbH ($1,361) |
| 2022 | $3,275 | 61 | Eli Lilly and Company ($2,472) |
| 2021 | $764.15 | 51 | AstraZeneca Pharmaceuticals LP ($150.58) |
| 2020 | $12,694 | 40 | Eli Lilly and Company ($12,120) |
| 2019 | $3,079 | 72 | Novo Nordisk AS ($2,286) |
| 2018 | $18,709 | 97 | Novo Nordisk Inc ($10,208) |
| 2017 | $10,982 | 156 | PFIZER INC. ($3,434) |
All Payment Transactions
662 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.50 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Inflammation | ||||||
| 11/03/2024 | Zealand Pharma A/S | — | Travel and Lodging | In-kind items and services | $1,195.46 | General |
| 11/03/2024 | Zealand Pharma A/S | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 10/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $3.23 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/09/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.03 | General |
| Category: PSYCHIATRY | ||||||
| 10/02/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $8.95 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/30/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Diabetes | ||||||
| 09/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $2.04 | General |
| Category: Diabetes | ||||||
| 09/23/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $10.19 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.73 | General |
| 09/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $0.77 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: NEUROSCIENCE | ||||||
| 08/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: NEUROSCIENCE | ||||||
| 08/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.23 | General |
| Category: NEUROSCIENCE | ||||||
| 08/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $745.45 | General |
| 08/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.05 | General |
| Category: Diabetes | ||||||
| 08/06/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/06/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.53 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $12,120 | 2 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,792 | 13 |
| A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | Regeneron Pharmaceuticals, Inc. | $1,472 | 10 |
| A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin GSK1325756 co administered with a standard of care antiviral oseltamivir , in the treatment of adults hospitalized with influenza | GlaxoSmithKline, LLC. | $1,228 | 10 |
| NN SELECT Results Meeting Philadelphia | Novo Nordisk AS | $690.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 3,930 | 7,313 | $525,352 | $202,496 |
| 2022 | 42 | 4,117 | 7,498 | $548,975 | $205,291 |
| 2021 | 40 | 3,790 | 6,876 | $491,318 | $157,594 |
| 2020 | 44 | 4,126 | 7,531 | $687,758 | $190,237 |
Total Patients
15,963
Total Services
29,218
Medicare Billing
$755,618
Procedure Codes
164
All Medicare Procedures & Services
164 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 272 | 584 | $142,496 | $50,189 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 142 | 235 | $80,840 | $29,406 | 36.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 79 | 221 | $42,653 | $20,644 | 48.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 160 | 160 | $37,440 | $20,263 | 54.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 89 | 106 | $39,750 | $14,232 | 35.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 234 | 466 | $23,766 | $7,670 | 32.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 297 | 714 | $22,848 | $7,378 | 32.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 301 | 835 | $8,350 | $6,989 | 83.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 294 | 710 | $16,330 | $5,389 | 33.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 25 | $15,258 | $4,185 | 27.4% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 182 | 364 | $10,556 | $3,458 | 32.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 182 | 246 | $9,840 | $3,218 | 32.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 160 | 160 | $5,760 | $2,903 | 50.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 44 | 44 | $2,904 | $2,846 | 98.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 67 | 77 | $6,853 | $2,234 | 32.6% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 13 | 13 | $4,524 | $2,118 | 46.8% |
| 83721 | Ldl cholesterol level | Office | 2023 | 133 | 197 | $5,713 | $2,027 | 35.5% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 13 | 13 | $5,109 | $1,963 | 38.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,631 | $1,730 | 37.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 44 | 44 | $1,540 | $1,342 | 87.1% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 126 | 236 | $4,248 | $1,331 | 31.3% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 131 | 263 | $3,945 | $1,327 | 33.6% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 64 | 64 | $3,520 | $1,211 | 34.4% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 126 | 236 | $3,540 | $1,195 | 33.8% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 163 | 309 | $3,090 | $958.51 | 31.0% |
About Dr. John Pullman, MD
Dr. John Pullman, MD is a Internal Medicine healthcare provider based in Butte, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518998426.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Pullman, MD has received a total of $62,347 in payments from pharmaceutical and medical device companies, with $9,185 received in 2024. These payments were reported across 662 transactions from 40 companies. The most common payment nature is "" ($17,303).
As a Medicare-enrolled provider, Pullman has provided services to 15,963 Medicare beneficiaries, totaling 29,218 services with total Medicare billing of $755,618. Data is available for 4 years (2020–2023), covering 164 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease, Critical Care Medicine
- Location Butte, MT
- Active Since 07/06/2006
- Last Updated 01/11/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1518998426
Products in Payments
- SOLIQUA (Drug) $5,729
- INVOKANA (Drug) $2,843
- ELIQUIS (Drug) $1,994
- Ozempic (Drug) $1,897
- Saxenda (Drug) $1,853
- ARMOUR THYROID (Drug) $1,679
- FARXIGA (Drug) $684.29
- Rezzayo (Drug) $562.50
- JARDIANCE (Drug) $432.97
- MOUNJARO (Drug) $315.87
- ENTRESTO (Drug) $271.89
- QULIPTA (Drug) $262.04
- TRULICITY (Drug) $239.98
- AIRSUPRA (Drug) $224.92
- XARELTO (Drug) $214.27
- SOLIQUA 100/33 (Biological) $203.90
- Rybelsus (Drug) $176.38
- LINZESS (Drug) $175.78
- UBRELVY (Drug) $160.78
- CHANTIX (Drug) $159.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Butte
David Chamberlain, M.d, M.D
Internal Medicine — Payments: $10,586
Internal Medicine $10,586
Mr. Joe Gregory, Do, DO
Internal Medicine — Payments: $2,529
Internal Medicine $2,529
Jacob Taverna, Md, MD
Internal Medicine — Payments: $1,514
Internal Medicine $1,514
Florian Cortese, M.d, M.D
Internal Medicine — Payments: $928.51
Internal Medicine $928.51
Paul Siddoway, M.d, M.D
Internal Medicine — Payments: $393.18
Internal Medicine $393.18
Dr. Charles Watson, Ph.d., D.o, PH.D., D.O
Internal Medicine — Payments: $31.11
Internal Medicine $31.11